The DOI matches its Crossref record.
Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics
Abstract
Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-κB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-κB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-κB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO. Cancer Res; 70(12); 5004–13. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
Cancer stem cell (CSC) resistance drivers
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116781 · Cited by 466
Yip, N. C., Fombon, I. S., Liu, P., Brown, S., Kannappan, V, Armesilla, A. L., Xu, B., Cassidy, J., Darling, J. L., & Wang, W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.126 · Cited by 421
Pancreatic cancer: understanding and overcoming chemoresistance
Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., & Sarkar, F. H. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.188 · Cited by 364
Salinomycin as a Drug for Targeting Human Cancer Stem Cells
Naujokat, C., & Steinhart, R. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/950658 · Cited by 351
Metadata
- Authors
- Rausch, V., Liu, L., Kallifatidis, G., Baumann, B., Mattern, J., Gladkich, J., Wirth, T., Schemmer, P., Büchler, M. W., Zöller, M., Salnikov, A. V., & Herr, I.
- Venue
- Cancer Research
- Published
- 2010-06-14
- Volume
- 70
- Issue
- 12
- Pages
- 5004-5013
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2116394959
- Cited by
- 209
- References
- 0
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-0066
- The paper
- Rausch, V., Liu, L., Kallifatidis, G., Baumann, B., Mattern, J., Gladkich, J., Wirth, T., Schemmer, P., Büchler, M. W., Zöller, M., Salnikov, A. V., & Herr, I. (2010). Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-0066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.